AP
JAZZ icon

Alydar Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Alydar Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-200,000
Closed -$13.7M – 122
2013
Q2 		$13.7M Buy
+200,000
New +$12.2M 0.74% 40

Other funds holding JAZZ

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
LPC
Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
WBC
Westpac Banking Corp Sydney, Australia $1.44B AUM 28.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alydar Partners's JAZZ Position: Q4 2014 in Review

Alydar Partners sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2014, closing a stake of 10,000 shares — an estimated $1.61M sold.

Alydar Partners first reported a position in JAZZ in Q2 2013 and held it in 2 quarters. The position peaked at $13.7M in Q2 2013. 357 funds tracked by Wall St. Rank hold JAZZ as of Q4 2014.

  • Alydar Partners reported no remaining Jazz Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Alydar Partners sold 10,000 Jazz Pharmaceuticals shares in Q4 2014, an estimated $1.61M.
  • Alydar Partners first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • Alydar Partners's Jazz Pharmaceuticals position peaked at $13.7M in Q2 2013.
  • 357 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2014.

Based on Alydar Partners's 13F filing for Q4 2014, filed 17 Feb 2015.